210 related articles for article (PubMed ID: 38089583)
1. Cell-free RNA signatures predict Alzheimer's disease.
Cisterna-García A; Beric A; Ali M; Pardo JA; Chen HH; Fernandez MV; Norton J; Gentsch J; Bergmann K; Budde J; Perlmutter JS; Morris JC; Cruchaga C; Botia JA; Ibanez L
iScience; 2023 Dec; 26(12):108534. PubMed ID: 38089583
[TBL] [Abstract][Full Text] [Related]
2. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
Gonzalez-Ortiz F; Turton M; Kac PR; Smirnov D; Premi E; Ghidoni R; Benussi L; Cantoni V; Saraceno C; Rivolta J; Ashton NJ; Borroni B; Galasko D; Harrison P; Zetterberg H; Blennow K; Karikari TK
Brain; 2023 Mar; 146(3):1152-1165. PubMed ID: 36572122
[TBL] [Abstract][Full Text] [Related]
3. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
Johnstone D; Milward EA; Berretta R; Moscato P;
PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
[TBL] [Abstract][Full Text] [Related]
4. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer's disease.
Pulliam L; Sun B; Mustapic M; Chawla S; Kapogiannis D
J Neurovirol; 2019 Oct; 25(5):702-709. PubMed ID: 30610738
[TBL] [Abstract][Full Text] [Related]
5. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
[TBL] [Abstract][Full Text] [Related]
6. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
7. Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials.
Castrillo JI; Lista S; Hampel H; Ritchie CW
Methods Mol Biol; 2018; 1750():31-66. PubMed ID: 29512064
[TBL] [Abstract][Full Text] [Related]
8. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases.
Snellman A; Lantero-Rodriguez J; Emeršič A; Vrillon A; Karikari TK; Ashton NJ; Gregorič Kramberger M; Čučnik S; Paquet C; Rot U; Zetterberg H; Blennow K
Brain; 2022 Aug; 145(8):2834-2848. PubMed ID: 35311972
[TBL] [Abstract][Full Text] [Related]
9. Presymptomatic Increase of an Extracellular RNA in Blood Plasma Associates with the Development of Alzheimer's Disease.
Yan Z; Zhou Z; Wu Q; Chen ZB; Koo EH; Zhong S
Curr Biol; 2020 May; 30(10):1771-1782.e3. PubMed ID: 32220323
[TBL] [Abstract][Full Text] [Related]
10. Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy.
Wang ZB; Tan L; Gao PY; Ma YH; Fu Y; Sun Y; Yu JT;
Alzheimers Dement; 2023 Oct; 19(10):4421-4435. PubMed ID: 37506291
[TBL] [Abstract][Full Text] [Related]
11. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
[TBL] [Abstract][Full Text] [Related]
12. A multiclass extreme gradient boosting model for evaluation of transcriptomic biomarkers in Alzheimer's disease prediction.
Zhang Y; Shen S; Li X; Wang S; Xiao Z; Cheng J; Li R
Neurosci Lett; 2024 Jan; 821():137609. PubMed ID: 38157927
[TBL] [Abstract][Full Text] [Related]
13. The Alzheimer's Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease.
Zhou Y; Xu J; Hou Y; Bekris L; Leverenz JB; Pieper AA; Cummings J; Cheng F
Alzheimers Dement (N Y); 2022; 8(1):e12350. PubMed ID: 36254161
[TBL] [Abstract][Full Text] [Related]
14. Deep learning-based brain transcriptomic signatures associated with the neuropathological and clinical severity of Alzheimer's disease.
Wang Q; Chen K; Su Y; Reiman EM; Dudley JT; Readhead B
Brain Commun; 2022 Feb; 4(1):fcab293. PubMed ID: 34993477
[TBL] [Abstract][Full Text] [Related]
15. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
16. Role of Plasma Clusterin in Alzheimer's Disease-A Pilot Study in a Tertiary Hospital in Northern India.
Vishnu VY; Modi M; Sharma S; Mohanty M; Goyal MK; Lal V; Khandelwal N; Mittal BR; Prabhakar S
PLoS One; 2016; 11(11):e0166369. PubMed ID: 27861589
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
18. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study.
Brosseron F; Maass A; Kleineidam L; Ravichandran KA; Kolbe CC; Wolfsgruber S; Santarelli F; Häsler LM; McManus R; Ising C; Röske S; Peters O; Cosma NC; Schneider LS; Wang X; Priller J; Spruth EJ; Altenstein S; Schneider A; Fliessbach K; Wiltfang J; Schott BH; Buerger K; Janowitz D; Dichgans M; Perneczky R; Rauchmann BS; Teipel S; Kilimann I; Görß D; Laske C; Munk MH; Düzel E; Yakupow R; Dobisch L; Metzger CD; Glanz W; Ewers M; Dechent P; Haynes JD; Scheffler K; Roy N; Rostamzadeh A; Spottke A; Ramirez A; Mengel D; Synofzik M; Jucker M; Latz E; Jessen F; Wagner M; Heneka MT;
Alzheimers Res Ther; 2023 Jan; 15(1):13. PubMed ID: 36631909
[TBL] [Abstract][Full Text] [Related]
19. Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
Patra K; Soosaipillai A; Sando SB; Lauridsen C; Berge G; Møller I; Grøntvedt GR; Bråthen G; Begcevic I; Moussaud S; Minthon L; Hansson O; Diamandis EP; White LR; Nielsen HM
Alzheimers Res Ther; 2018 Jan; 10(1):9. PubMed ID: 29378650
[TBL] [Abstract][Full Text] [Related]
20. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
